By the end of the antifungal agents: triazoles chapter, the learner shall be able to: 1. Compare and contrast the main causes of pharmacokinetic variability among triazole antifungals that could jeopardize the efficacy and/or safety of treatment. 2. Identify specific factors for each triazole antifungal and formulation that may predispose patients to pharmacokinetic interactions. 3. Describe strategies of how triazole antifungal dosing can be optimized when inadequate drug exposures are identified by therapeutic drug monitoring.
Antifungal agents:triazoles
Lewis, RE
Writing – Original Draft Preparation
2018
Abstract
By the end of the antifungal agents: triazoles chapter, the learner shall be able to: 1. Compare and contrast the main causes of pharmacokinetic variability among triazole antifungals that could jeopardize the efficacy and/or safety of treatment. 2. Identify specific factors for each triazole antifungal and formulation that may predispose patients to pharmacokinetic interactions. 3. Describe strategies of how triazole antifungal dosing can be optimized when inadequate drug exposures are identified by therapeutic drug monitoring.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
